Pascal and Francis Bibliographic Databases

Help

Search results

Your search

au.\*:("TINDALL, Donald")

Publication Year[py]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Discipline (document) [di]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Author Country

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Results 1 to 25 of 52

  • Page / 3
Export

Selection :

  • and

New Developments in the Medical Management of Prostate CancerKOHLI, Manish; TINDALL, Donald J.Mayo Clinic proceedings. 2010, Vol 85, Num 1, pp 77-86, issn 0025-6196, 10 p.Article

Regulation of androgen receptor signaling in prostate cancerDEHM, Scott M; TINDALL, Donald J.Expert review of anticancer therapy. 2005, Vol 5, Num 1, pp 63-74, issn 1473-7140, 12 p.Article

State of research for prostate cancer : Excerpt from the report of the prostate cancer progress review groupTINDALL, Donald J; SCARDINO, Peter J.Urology (Ridgewood, NJ). 2001, Vol 57, Num 4A, pp 28-30, issn 0090-4295Article

Androgen Receptor Rediscovered: The New Biology and Targeting the Androgen Receptor TherapeuticallyRYAN, Charles J; TINDALL, Donald J.Journal of clinical oncology. 2011, Vol 29, Num 27, pp 3651-3658, issn 0732-183X, 8 p.Article

The role of androgens and the androgen receptor in prostate cancerDEBES, Jose D; TINDALL, Donald J.Cancer letters. 2002, Vol 187, Num 1-2, pp 1-7, issn 0304-3835, 7 p.Article

Gene expression in prostate cancer cells treated with the dual 5 alpha-reductase inhibitor dutasterideSCHMIDT, Lucy J; MURILLO, Horacio; TINDALL, Donald J et al.Journal of andrology. 2004, Vol 25, Num 6, pp 944-953, issn 0196-3635, 10 p.Article

Tyrphostin AG825 triggers p38 mitogen-activated protein kinase-dependent apoptosis in androgen-independent prostate cancer cells C4 and C4-2MURILLO, Horacio; SCHMIDT, Lucy J; TINDALL, Donald J et al.Cancer research (Baltimore). 2001, Vol 61, Num 20, pp 7408-7412, issn 0008-5472Article

The Rationale for Inhibiting 5α-Reductase Isoenzymes in the Prevention and Treatment of Prostate CancerTINDALL, Donald J; RITTMASTER, Roger S.The Journal of urology. 2008, Vol 179, Num 4, pp 1235-1242, issn 0022-5347, 8 p.Article

Androgen Receptor (AR) Coregulators : A Diversity of Functions Converging on and Regulating the AR Transcriptional ComplexHEEMERS, Hannelore V; TINDALL, Donald J.Endocrine reviews. 2007, Vol 28, Num 7, pp 778-808, issn 0163-769X, 31 p.Article

Androgen receptor signaling in androgen-refractory prostate cancerGROSSMANN, Michael E; HAOJIE HUANG; TINDALL, Donald J et al.Journal of the National Cancer Institute. 2001, Vol 93, Num 22, pp 1687-1697, issn 0027-8874Article

The Effect of Dutasteride on the Usefulness of Prostate Specific Antigen for the Diagnosis of High Grade and Clinically Relevant Prostate Cancer in Men With a Previous Negative Biopsy: Results From the REDUCE StudyANDRIOLE, Gerald L; BOSTWICK, David; FREEDLAND, Stephen J et al.The Journal of urology. 2011, Vol 185, Num 1, pp 126-131, issn 0022-5347, 6 p.Article

Inhibition of fatty acid synthase activity in prostate cancer cells by dutasterideSCHMIDT, Lucy J; BALLMAN, Karla V; TINDALL, Donald J et al.The Prostate. 2007, Vol 67, Num 10, pp 1111-1120, issn 0270-4137, 10 p.Article

Chemoprevention of prostate cancer in men at high risk: Rationale and design of the reduction by dutasteride of prostate cancer events (reduce) trialANDRIOLE, Gerald; BOSTWICK, David; BRAWLEY, Otis et al.The Journal of urology. 2004, Vol 172, Num 4, pp 1314-1317, issn 0022-5347, 4 p., 1Article

Dihydrotestosterone and the prostate: The scientific rationale for 5α-reductase inhibitors in the treatment of benign prostatic hyperplasiaANDRIOLE, Gerald; BRUCHOVSKY, Nicholas; CHUNG, Leland W. K et al.The Journal of urology. 2004, Vol 172, Num 4, pp 1399-1403, issn 0022-5347, 5 p., 1Article

Metastatic prostate carcinoma to bone: Clinical and pathologic features associated with cancer-specific survivalCHEVILLE, John C; TINDALL, Donald; BOELTER, Christopher et al.Cancer. 2002, Vol 95, Num 5, pp 1028-1036, issn 0008-543XArticle

Androgen Induction of the Androgen Receptor Coactivator Four and a Half LIM Domain Protein-2: Evidence for a Role for Serum Response Factor in Prostate CancerHEEMERS, Hannelore V; REGAN, Kevin M; DEHM, Scott M et al.Cancer research (Baltimore). 2007, Vol 67, Num 21, pp 10592-10599, issn 0008-5472, 8 p.Article

Vascular Endothelial Growth Factor-C Protects Prostate Cancer Cells from Oxidative Stress by the Activation of Mammalian Target of Rapamycin Complex-2 and AKT-1MUDERS, Michael H; HEYU ZHANG; ENFENG WANG et al.Cancer research (Chicago, Ill.). 2009, Vol 69, Num 15, pp 6042-6048, issn 0008-5472, 7 p.Article

Selective role of an NH2-terminal WxxLF motif for aberrant androgen receptor activation in androgen depletion-independent prostate cancer cellsDEHM, Scott M; REGAN, Kevin M; SCHMIDT, Lucy J et al.Cancer research (Baltimore). 2007, Vol 67, Num 20, pp 10067-10077, issn 0008-5472, 11 p.Article

Steroid 5 α-reductase inhibitors targeting BPH and prostate cancerSCHMIDT, Lucy J; TINDALL, Donald J.Journal of steroid biochemistry and molecular biology. 2011, Vol 125, Num 1-2, pp 32-38, issn 0960-0760, 7 p.Article

Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cellsZEGARRA-MORO, Ofelia L; SCHMIDT, Lucy J; HAOJIE HUANG et al.Cancer research (Baltimore). 2002, Vol 62, Num 4, pp 1008-1013, issn 0008-5472Article

Androgens repress Bcl-2 expression via activation of the retinoblastoma (RB) protein in prostate cancer cellsHAOJIE HUANG; ZEGARRA-MORO, Ofelia L; BENSON, Douglas et al.Oncogene (Basingstoke). 2004, Vol 23, Num 12, pp 2161-2176, issn 0950-9232, 16 p.Article

p300 Mediates androgen-independent transactivation of the androgen receptor by interleukin 6DEBES, Jose D; SCHMIDT, Lucy J; HAOJIE HUANG et al.Cancer research (Baltimore). 2002, Vol 62, Num 20, pp 5632-5636, issn 0008-5472, 5 p.Article

CDK2-dependent phosphorylation of F0X01 as an apoptotic response to DNA damageHAOJIE HUANG; REGAN, Kevin M; ZHENKUN LOU et al.Science (Washington, D.C.). 2006, Vol 314, Num 5797, pp 294-297, issn 0036-8075, 4 p.Article

Induction of FLIP Expression by Androgens Protects Prostate Cancer Cells From TRAIL-Mediated ApoptosisRACLAW, Kristin A; HEEMERS, Hannelore V; KIDD, Emily M et al.The Prostate. 2008, Vol 68, Num 15, pp 1696-1706, issn 0270-4137, 11 p.Article

Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporterSPITZWEG, Christine; O'CONNOR, Michael K; BERGERT, Elizabeth R et al.Cancer research (Baltimore). 2000, Vol 60, Num 22, pp 6526-6530, issn 0008-5472Article

  • Page / 3